Generic placeholder image Background

The American Society for Clinical Pathology (ASCP), the College of American Pathologists (CAP), the Association of Molecular Pathology (AMP), and the American Society of Clinical Oncology (ASCO) collaborated to develop a clinical practice guideline on molecular biomarker testing for patients with early and advanced colorectal cancer.

Colorectal cancer is the second leading cause of cancer death when men and women in the U.S. are combined.1 This evidence-based clinical practice guideline will help establish standard molecular biomarker testing, guide targeted therapy decisions, and advance personalized care for these patients.

Twenty-one guideline statements were established (eight recommendations, 10 expert consensus opinions, and three “no recommendation”) based on evidence from a comprehensive literature review, which included over 4,000 articles. The guideline supports mutational testing for genes in the epidermal growth factor receptor (EGFR) pathway to inform targeted therapy decisions. Additional recommendations are intended to streamline molecular testing processes and contribute to improving patient outcomes.

The COMPLETE GUIDELINE was published for early online release on Feb. 6, 2017, in American Journal of Clinical Pathology (AJCP), Archives of Pathology & Laboratory Medicine, Journal of Molecular Diagnostics (JMD), and Journal of Clinical Oncology (JCO).

1Cancer Facts & Figures 2017. American Cancer Society, 2017.

Video for Physicians